Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185)
:2185
Top Page
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
(2185)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$6.00
▲(5.08% Upside)
Action:UpgradedDate:12/30/25
The score is held down primarily by the lack of revenue and ongoing cash burn despite improving losses, alongside weak technical momentum (below key moving averages with negative MACD). Low leverage is a stabilizing factor, but valuation is difficult to assess with negative earnings and no dividend data.
Positive Factors
Narrowing losses
A consistent multi-year reduction in net losses signals improving cost control and R&D efficiency. This durable trend lowers the quantum of future funding needed, improves runway assumptions, and increases the probability management can reach clinical or commercial inflection points without immediate restructuring.
Negative Factors
No revenue
Absent revenue, the firm remains wholly pre-commercial and value depends on successful clinical outcomes or licensing deals. This structural lack of operating income maintains high execution risk, limited earnings visibility, and persistent dependency on external capital for extended periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrowing losses
A consistent multi-year reduction in net losses signals improving cost control and R&D efficiency. This durable trend lowers the quantum of future funding needed, improves runway assumptions, and increases the probability management can reach clinical or commercial inflection points without immediate restructuring.
Read all positive factors
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$942.02M
Dividend YieldN/A
Average Volume (3M)2.14M
Price to Earnings (P/E)―
Beta (1Y)1.54
Revenue GrowthN/A
EPS Growth22.65%
CountryHK
Employees63
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.12
Shares Outstanding235,703,410
10 Day Avg. Volume3,698,147
30 Day Avg. Volume2,141,365
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$2.07B
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) the...
How the Company Makes Money
Shanghai Bio-Heart Biological Technology Co., Ltd. generates revenue by developing and selling medical devices and technologies related to cardiovascular health. The company earns income through the sale of its proprietary products to healthcare p...
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.70M | 0.00 | -23.60M | -24.25M | 0.00 | -9.71M |
| EBITDA | -44.18M | -44.54M | -148.21M | -237.34M | -400.88M | -319.76M |
| Net Income | -89.33M | -87.94M | -194.36M | -237.50M | -361.45M | -365.79M |
Balance Sheet | ||||||
| Total Assets | 878.42M | 733.78M | 817.90M | 981.52M | 1.11B | 785.04M |
| Cash, Cash Equivalents and Short-Term Investments | 312.87M | 202.39M | 369.44M | 451.32M | 708.53M | 453.67M |
| Total Debt | 7.67M | 8.28M | 1.76M | 18.11M | 22.45M | 1.32M |
| Total Liabilities | 224.62M | 53.24M | 44.04M | 66.47M | 80.04M | 40.94M |
| Stockholders Equity | 477.65M | 660.47M | 748.41M | 883.21M | 995.69M | 700.09M |
Cash Flow | ||||||
| Free Cash Flow | -83.34M | -166.69M | -66.74M | -170.65M | -147.28M | -60.74M |
| Operating Cash Flow | -59.77M | -119.55M | -49.03M | -140.62M | -105.45M | -54.28M |
| Investing Cash Flow | -23.02M | -46.03M | -28.86M | -100.69M | -33.73M | -225.15M |
| Financing Cash Flow | -1.22M | -2.44M | -5.82M | -35.18M | 383.68M | 722.99M |
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Technical Analysis
Negative
5.71
Price Trends
5.38
Negative
6.05
Negative
5.87
Negative
Market Momentum
-0.35
Positive
23.85
Positive
9.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2185, the sentiment is Negative. The current price of 5.71 is above the 20-day moving average (MA) of 4.78, above the 50-day MA of 5.38, and below the 200-day MA of 5.87, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 23.85 is Positive, neither overbought nor oversold. The STOCH value of 9.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2185.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.93B | -16.66 | 0.99% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.98B | -5.30 | 2.04% | ― | 1447.56% | ― | |
47 Neutral | HK$1.61B | -2.78 | -15.44% | ― | -38.38% | -22.12% | |
46 Neutral | HK$1.60B | -2.27 | -0.08% | ― | ― | 47.42% | |
44 Neutral | HK$942.02M | -7.24 | -15.70% | ― | ― | 22.65% | |
43 Neutral | HK$1.54B | -2.55 | 287.10% | ― | ― | 27.90% |
* Healthcare Sector Average
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
3.87
0.97
33.45%
HK:6998
Genor Biopharma Holdings Limited
2.48
0.30
13.76%
HK:1875
TOT BIOPHARM International Co. Ltd.
5.08
3.06
151.49%
HK:6622
Zhaoke Ophthalmology Ltd.
2.93
1.03
54.21%
HK:6978
Immunotech Biopharm Ltd
2.49
-1.17
-31.97%
HK:2511
Hightide Therapeutics Inc
3.15
1.38
77.97%
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Corporate Events
Shanghai Bio-Heart’s Iberis Renal Denervation System Registered in Indonesia
Jan 26, 2026
Shanghai Bio-Heart announced that its subsidiary Shanghai AngioCare Medical Technology has completed registration of the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System in Indonesia, supported by commercialization...
Shanghai Bio-heart Registers Iberis® RDN System in New Zealand
Nov 26, 2025
Shanghai Bio-heart Biological Technology Co., Ltd. has announced the successful registration of its Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System in New Zealand. This system is notable for being the only renal d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.